Stock Traders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR) was the target of some unusual options trading on Monday. Stock traders bought 10,363 call options on the company. This is an increase of 221% compared to the average daily volume of 3,229 call options.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Citigroup reaffirmed a “market outperform” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Piper Sandler began coverage on Esperion Therapeutics in a research note on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 price objective on the stock. Wall Street Zen cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Friday, September 19th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.33.

Esperion Therapeutics Stock Down 1.8%

Shares of ESPR opened at $3.78 on Tuesday. The stock has a market capitalization of $903.65 million, a P/E ratio of -7.56 and a beta of 1.00. Esperion Therapeutics has a twelve month low of $0.69 and a twelve month high of $4.13. The firm has a fifty day simple moving average of $3.12 and a two-hundred day simple moving average of $2.25.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.07). The firm had revenue of $87.31 million for the quarter, compared to analysts’ expectations of $78.33 million. Sell-side analysts expect that Esperion Therapeutics will post -0.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Esperion Therapeutics

A number of large investors have recently made changes to their positions in the business. CIBC Bancorp USA Inc. bought a new position in shares of Esperion Therapeutics during the third quarter valued at approximately $56,000. Caitong International Asset Management Co. Ltd raised its holdings in Esperion Therapeutics by 40,487.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 31,252 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 31,175 shares in the last quarter. Eaton Financial Holdings Company LLC bought a new position in Esperion Therapeutics in the 3rd quarter worth $113,000. Voleon Capital Management LP purchased a new stake in shares of Esperion Therapeutics in the 3rd quarter worth about $551,000. Finally, Mariner LLC bought a new stake in shares of Esperion Therapeutics during the 3rd quarter valued at about $802,000. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.